Actinium Pharmaceuticals shares rose after new preclinical data showed its ATNM-400 radiotherapy delivered strong anti-tumor effects across HR+, TNBC, and treatment-resistant breast cancer models. The Ac-225 radioconjugate also showed potential in other solid tumors with minimal side effects. The stock gained over 3% in Fridays premarket.